Viking Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 27.36 million compared to USD 19.53 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.25 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.64 USD | -8.18% | -4.33% | +295.70% |
May. 06 | Viking Therapeutics Insider Sold Shares Worth $4,986,008, According to a Recent SEC Filing | MT |
May. 03 | Wall St set to open sharply higher on soft jobs data | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+295.70% | 8.12B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- VKTX Stock
- News Viking Therapeutics, Inc.
- Viking Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024